Wilex
Latest round
- Series C
Last raised
- May 2005
Total raised
- $39M
Investors
- 7
About Wilex
Wilex AG is a biotechnology company focused on developing innovative therapies for the treatment of cancer using its proprietary Antibody-Drug Conjugate (ADC) technology.Wilex AG specializes in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing various cancer types. Founded in 1997 in Munich, Germany, the company has undergone strategic pivots to refine its focus on ADC technology. The CEO, Jan Schmidt-Brand, leads the company in its initiatives.60 mn from the Federal Ministry of Education and Research in November 2006.Wilex AG develops Antibody-Drug Conjugates (ADCs) that target and destroy cancer cells with high specificity, utilizing their proprietary ATAC technology. This technology leverages Amanitin, a potent substance derived from mushrooms, to overcome drug resistance in tumors, providing new treatment options for patients who do not respond to standard therapies.60.Looking ahead, Wilex AG plans to expand its product lineup with new ADC therapies designed to target additional cancer types, although specific product release dates have not been disclosed. The company is also focused on entering new markets, particularly in regions across Europe and North America, intending to broaden its reach by 2025.
Who invested in Wilex
7 investors across 1 round
See all investors in Wilex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
May 10, 2005
Amount
$39M
Investors
Questions about Wilex
Who invested in Wilex?
Wilex has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Wilex raised?
Wilex has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Wilex last raise money?
Wilex's most recent round on record is a Series C, in May 2005.
What does Wilex do?
Wilex AG is a biotechnology company focused on developing innovative therapies for the treatment of cancer using its proprietary Antibody-Drug Conjugate (ADC) technology.
Where is Wilex headquartered?
Wilex is headquartered in Munich, Germany.
Which VCs invest in companies like Wilex?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at Wilex's stage. Their profiles are linked below.
VCs backing healthcare startups at Series C
Raising like Wilex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.